相关实验视频

Updated: Jan 15, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

MELD 3.i:贝叶斯框架,用于更新末期肝病得分模型

Tomohiro Tanaka^1,2, Jennifer C Lai³, David Axelrod^4,5,6

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

JHEP reports : innovation in hepatology

|October 10, 2025

概括

新的MELD 3.1评分提高了肝移植等候名单死亡率的预测,特别是对女性来说,使用适应贝叶斯框架 (MELD 3.i) 进行持续更新.

科学领域:

肝病学肝病学是一种肝病学.
移植手术移植手术
生物统计学生物统计学

背景情况:

末期肝病模型 (MELD) 评分对于肝移植分配至关重要,MELD 3.0是最新的代.
由于肝病流行病学和患者人口统计的不断变化,MELD的持续改进是必要的.

研究的目的:

引入MELD 3.1,这是MELD 3.i适应框架的第一个代,用于完善肝移植候选人的优先级.
评估MELD 3.1对90天等候名单死亡率的预测准确度,与MELD 3.0.0相比.

主要方法:

一项对2023年7月至2024年6月期间美国成年肝移植候选人的回顾性队列研究.
贝叶斯比例危险模型使用MELD 3.0作为信息先验来开发MELD 3.1.
模型性能使用一致性 (C-) 统计和重新分类分析进行评估.

主要成果:

对于90天候名单死亡率,MELD 3.1显示了改善的C统计 (0.7195对MELD 3.0的0.7152,p=0.036).
MELD 3.1导致患者死亡或退学的净3.1%升级分类,主要受益于女性候选人.
该模型显示,在各种年龄组和肝脏疾病病因方面,预测准确度有所提高.

结论:

MELD 3.i框架提供了一种可持续的,适应性的方法,用于使用当代数据和贝叶斯方法定期改进MELD得分.
MELD 3.1 提高了预测准确性和响应不断变化的患者人口统计和临床实践,解决了器官分配中的性别差异.

关键词:

分配分配分配分配分配分配分配分配分配分配分配分配分配分配分配贝斯海湾是贝斯海湾的一个地区.生物统计学生物统计学肝脏移植肝脏移植在MELD 3.0中,MELD 3.0是MELD3.0的版本,MELD 3.0是MELD的版本.

更多相关视频

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration

Published on: May 24, 2024

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Model Approaches for Pharmacokinetic Data: Physiological Models

Model Approaches for Pharmacokinetic Data: Physiological Models

Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...